Just months after Grail raised a $900 million Series B round, the startup that aims to detect cancer early on is looking for additional funding, CNBC reports. Prior to the $900 million round, Grail raised $100 million last year to develop initial studies of its blood test technology. Citing sources, CNBC says Grail is mostly focused on sovereign funds. Grail has reportedly been in touch… Read More...